m Honestly ot sure i sold at 64 last run when i said load up in my post nad made bak then i had a huge position again at 39 when it comes down and sold at 46.... m thinking maybe 48 because of constellation brands price purchasing it at $48
TDOC medical billing software showing good entry per DPO and CCI from recent decline in value. Good CAGR rate, no Div., positive, near 50% Earnings growth rate the last 5-yr. and nearing profitability, not expected until 2020-2021.
4.4B company in medical billing
Nov 5th, 3:12 pm
$PEN Q3 top line beat of $111.8M vs consensus $102M, 33% yoy. Neuro grew 27%. Vascular grew 47%. Raised 2018 guide from $420-25M to $437-38M
Nov 6th, 9:15 am
$PEN Check out this $5 billion innovator in catheter-based stroke treatment. Penumbra could be good tuck-in for $JNJ $MDT or even $EW
Wells Fargo med-tech analyst Larry Biegelsen has been ...
Watch CCI momentum with MACD here. . . future profits and earnings TBD. Await patents and studies. Expect they'll eventually have to sell the farm here to pay for all the cannabis / hemp studies. Ent Value / Mkt Value is 1.02. A new medical advisory board for new medical products. One patent issued 2017 for treatment of neurobahaviors and could lead to ...
watching for entry, pulse, dead cat falling wedge for 3rd cycle (2014, 2016, 2018)...TBD
About: Terra Tech Corp. operates as a vertically integrated cannabis-focused agriculture company. The company operates in two segments, Herbs and Produce Products; and Cannabis Dispensary, Cultivation and Production. The Herbs and Produce Products segment offers hydroponic ...
* Fib retracement bottomed at $0.70US and now at 0.79 uptick
* Uptick started and CCI moved up on day chart to buy
* Cannabis Industry getting traction with CBD sales
* Test lab approvals CA, OR (trace metals, solvents, pesticides, THC)
* 50% partnership with Keystone Labs Canada
Viewers come to own conclusion.
Biogen's (344.10 at close at the date of this writing) and Eisai's recent success with BAN24O1, an experimental medication for Alzheimer's which is currently in mid-stage clinical trials, in addition to a recent price target raise by Citi, and overall bullish analyst sentiment led to a rally between July 6-9, 2018.
Although the clinical trial's success was ...
$CELZ is currently on a clear and clean breakout in anticipation of the May 18th- 21st Presentation at the American Urological Association Convention in San Francisco.
An 8K was released recently showing that shares were issued at .10 and as high as .30 levels
The following link shows that the CEO has been buying on the way up as ...
$CELZ broke above prior high on the last leg after a release of 8-Ks showing the clearing up of the rest of the company's debt and notes.
Item 1.01 Entry into a Material Definitive Agreement
Effective April 11, 2018, Creative Medical Technology Holdings, Inc. (the “ Company ”) amended promissory notes issued by it and by its operating subsidiary, Creative ...
Oh Novanta. So many possibilities for such a great company. Please forgive the maddening amount of clustered lines. The primary trend line is massive and seemingly unstoppable for a reason. Even though it's gone parabolic, its story is rock solid and almost sexy with everything they have a hand in.
As a leader in medical and advanced, industrial markets, Novanta ...
With brand recognition and consistent sales in place, Mazor has stated that 2018 will be a transition year for them, not growth. Therefore, expect the company to aim for stability as it continues to spread its products. Per the last call: "2018 is expected to be a year of transition and our performance is expected to be driven primarily by increased revenues from ...